Dear There,

Effective June 17, 2022, the US Food and Drug Administration (FDA) approved an expanded indication for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) to include children 6 weeks through 17 years of age.

Please click the link below for important drug and coding information:

Please click on the link below for full Prescribing Information:

If you have any questions regarding the information above, please contact us at info@reimbursementcodes.com or 1-860-563-1223.

Kind regards,

If you have received this notice in error, or would prefer not to receive further communications from this sender, please send an email to info@reimbursementcodes.com and detail your request. Include your name, organization name and email address.